tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsPre-Market BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

AMRN Stock Latest News

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
Press ReleasesAmarin Files Definitive Proxy Materials and Mails Letter to Shareholders
40m ago
AMRN
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
Press ReleasesAmarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
4d ago
AMRN
Amarin says VAZKEPA approved by Medsafe in New Zealand
The FlyAmarin says VAZKEPA approved by Medsafe in New Zealand
4d ago
AMRN
Amarin to Present at SVB Securities Global Biopharma Conference
Press ReleasesAmarin to Present at SVB Securities Global Biopharma Conference
4d ago
AMRN
Amarin calls Sarissa statement ‘inaccurate and misleading’
The FlyAmarin calls Sarissa statement ‘inaccurate and misleading’
12d ago
AMRN
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
Press ReleasesAmarin Responds to Inaccurate and Misleading Statement by Sarissa
12d ago
AMRN
Sarissa Capital Management issues statement on Amarin
The FlySarissa Capital Management issues statement on Amarin
13d ago
AMRN
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
Press ReleasesAmarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
20d ago
AMRN
Sarissa Capital submits notice to call Special Meeting of Amarin shareholders
The FlySarissa Capital submits notice to call Special Meeting of Amarin shareholders
21d ago
AMRN
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
Press ReleasesAmarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
21d ago
AMRN
Amarin expects cash to support continued operations
The FlyAmarin expects cash to support continued operations
21d ago
AMRN
Amarin announces 2022 achievements, 2023 priorities
The FlyAmarin announces 2022 achievements, 2023 priorities
21d ago
AMRN
Amarin sees Q4 revenue $88M-$90M, consensus $86.92M
The FlyAmarin sees Q4 revenue $88M-$90M, consensus $86.92M
21d ago
AMRN
Amarin appoints Stewart to board of directors
The FlyAmarin appoints Stewart to board of directors
21d ago
AMRN
RYTM
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
Press ReleasesAmarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
21d ago
AMRN
Jefferies upgrades ‘intriguing small cap value play’ Amarin to Buy
The FlyJefferies upgrades ‘intriguing small cap value play’ Amarin to Buy
25d ago
AMRN
Amarin upgraded to Buy from Hold at Jefferies
The FlyAmarin upgraded to Buy from Hold at Jefferies
25d ago
AMRN
Amarin in patent infringement settlement with Health Net, no terms
The FlyAmarin in patent infringement settlement with Health Net, no terms
28d ago
AMRN
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
Press ReleasesAmarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
2M ago
AMRN
Amarin announces VAZKEPA receives regulatory approval in Switzerland
The FlyAmarin announces VAZKEPA receives regulatory approval in Switzerland
2M ago
AMRN
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
Press ReleasesAmarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
3M ago
AMRN
HLS Therapeutics highlights data on RESPECT-EPA study
The FlyHLS Therapeutics highlights data on RESPECT-EPA study
3M ago
AMRN
Amarin highlights key data presented at AHA 2022 on VASCEPA/VAZKEPA
The FlyAmarin highlights key data presented at AHA 2022 on VASCEPA/VAZKEPA
3M ago
AMRN
CinCor Pharma appoints Kalb as EVP, CFO
The FlyCinCor Pharma appoints Kalb as EVP, CFO
3M ago
AMRN
CINC
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
Press ReleasesAmarin Reports Third Quarter 2022 Financial Results and Provides Business Update
3M ago
AMRN
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
Press ReleasesAmarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
3M ago
AMRN
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
Press ReleasesAmarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
3M ago
AMRN
Amarin Board of Directors Issues Statement in Response to Sarissa
Press ReleasesAmarin Board of Directors Issues Statement in Response to Sarissa
4M ago
AMRN
New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
Press ReleasesNew REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers
5M ago
AMRN
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.